Abstract:R ed blood cells (RBCs) are nature’s long-circulating delivery vehicles. They possess various remarkable properties and continue to inspire the design and engineering of man-made delivery systems. Inherently suited for intravascular delivery, RBCs are intrinsically biocompatible, biodegradable, and nonimmunogenic. They form natural compartments capable of protecting encapsulated cargos, and this allows them to circulate in the bloodstream for a long period of time (up to 120 days). In addition, their semipermeable membrane affords sustained release to smallmolecule drugs, yet they are ideal for retaining large proteins while providing them access to the substrates. Delivery vehicles possessing one or several of these properties have long been desired for efficacious therapeutics. A long-sought strategy for RBC-mimicking delivery vehicles is to load natural RBCs with therapeutic agents without compromising the structural integrity and biological functions of the RBCs. Various loading techniques, including automated loading devices, have been developed to enable the encapsulation of payloads with molecular weights of over 180 kDa into RBCs with maintenance of the carriers’ biological competence. In addition to the interior of RBCs, their exterior surface has also been coupled with therapeutic molecules, either covalently or physically, for various delivery applications. These RBC-based delivery vehicles, namely carrier RBCs, have been developed for the delivery of numerous therapeutic agents, including proteins, nucleic acids, and small-molecule drugs. Several of them have entered clinical tests to treat various diseases, including cancers and enzyme deficiencies. Meanwhile, advances in molecular biology have provided unprecedented understanding of the connections between the physicochemical characteristics of RBCs and their biological functions. This understanding, in turn, has inspired researchers to model drug carriers after RBCs. Designs that mimic the physicochemical characteristics and biological functions of RBCs, particularly those that enable their passage through narrow constrictions while maintaining a long in vivo survival, have been integrated into the engineering of drug carriers and have resulted in novel delivery systems with improved drug tolerability, circulation lifetime, and efficacy. Recently, the pursuit of RBC-mimicking nanoparticles led us to develop an intriguing approach for functionalizing synthetic nanoparticles with natural RBC membranes. In this approach, we first collected intact cellular membranes and then coated them onto polymeric nanoparticle cores, such as those made from poly(lactic-co-glycolic acid) (PLGA); this resulted in red-blood-cell-membrane–coated nanoparticles (RBC-NPs; Figure 1). Our aim was to fabricate cellmimicking nanoparticles through a top-down approach that bypassed the labor-intensive processes of protein identification, purification, and conjugation. The natural membranes also provide a bilayered medium for transmembrane protein anchorage while preventing common chemical modifications that could compromise the integrity and functionalities of these proteins. The independent preparation of cellular membranes and particle cores before coating offers a new level of engineering flexibility toward highly functional biomimetic nanoparticles. Since their initial development, RBC-NPs have provided an unprecedented capability for harnessing the natural functionalities of native cells that would otherwise be difficult to replicate. They have since inspired us to develop novel nanotherapeutics for better disease intervention. In this Perspective, we review our recent progress in developing RBC-NPs for three distinct biomedical applications: long-circulating nanocarriers for drug delivery, biomimetic nanosponges for detoxification, and nanotoxoids for safe and effective toxin vaccination.

From blood to brain: blood cell-based biomimetic drug delivery systems

Mesenchymal stem cell-based drug delivery strategy: from cells to biomimetic

Engineering red‐blood‐cell‐membrane–coated nanoparticles for broad biomedical applications

Advances of Blood Cell-Based Drug Delivery Systems

Cell membrane-based biomimetic vehicles for effective central nervous system target delivery: Insights and challenges

Advancements in strategies for overcoming the blood-brain barrier to deliver brain-targeted drugs

Recent advances in biomimetic nanodelivery systems: New brain-targeting strategies

Advances in Brain Delivery Systems Based on Biomimetic Nanoparticles

Living Cells and Cell-Derived Vesicles: A Trojan Horse Technique for Brain Delivery

Revolutionizing Neurocare: Biomimetic Nanodelivery via Cell Membranes

Biomimetic drug-delivery systems for the management of brain diseases

Brain-targeted nanoparticle drug delivery systems:research advances

The blood–brain barrier: structure, regulation, and drug delivery

Getting drugs to the brain: advances and prospects of organic nanoparticle delivery systems for assisting drugs to cross the blood-brain barrier

Drug Delivery to the Brain Across the Blood-Brain Barrier Using Nanomaterials.

Perspectives on Brain-Targeting Drug Delivery Systems.

Recent Advances on Drug Delivery Nanocarriers for Cerebral Disorders.

Advanced Noninvasive Strategies for the Brain Delivery of Therapeutic Proteins and Peptides

Blood–Brain Barrier-Targeting Nanoparticles: Biomaterial Properties and Biomedical Applications in Translational Neuroscience

Development of Novel Therapeutics Targeting the Blood–Brain Barrier: From Barrier to Carrier

Research Advances in Brain-Targeted Nanoscale Drug Delivery System